Topic
Drug compounding rules and FDA actions to monitor
FDA shapes compounding through its guidance, its risk alerts, its enforcement actions and its drug shortage list, which affects when compounded versions of a drug can be made. These are the pages where FDA, the Federal Register and the national pharmacy bodies post those changes.
For semaglutide and tirzepatide, the shortage list and FDA's statements on unapproved GLP-1 drugs are the pages to read.
14 pages checked daily with Team and up
On Team already? Open this topic
The pages in this topic
FDA's compounding actions, risk alerts and policies, the drug shortage list, its letters on drug marketing, the Federal Register's compounding and GLP-1 notices, and the national pharmacy bodies.
We last checked every page here on October 20, 2026.
-
- FDA compounding: inspections, recalls and other actions (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- FDA's concerns with unapproved GLP-1 drugs (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- FDA compounding risk alerts (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- Federal Register: compounding notices (opens the page in a new tab)
federalregister.gov · Office of the Federal Register
- FDA drug shortages list (opens the page in a new tab)
dps.fda.gov · FDA Center for Drug Evaluation and Research
- FDA compounding laws, policies and guidance (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- FDA registered outsourcing facilities (503B) (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- Federal Register: GLP-1 drug notices (opens the page in a new tab)
federalregister.gov · Office of the Federal Register
- FDA rules and proposed rules (opens the page in a new tab)
federalregister.gov · Office of the Federal Register
- FDA untitled letters on drug promotion (opens the page in a new tab)
fda.gov · FDA Office of Prescription Drug Promotion
- FDA warning letters (opens the page in a new tab)
fda.gov · U.S. Food and Drug Administration
- FDA Pharmacy Compounding Advisory Committee (opens the page in a new tab)
fda.gov · FDA Center for Drug Evaluation and Research
- NABP news (opens the page in a new tab)
nabp.pharmacy · National Association of Boards of Pharmacy
- USP compounding standards (opens the page in a new tab)
usp.org · United States Pharmacopeia
- FDA compounding: inspections, recalls and other actions (opens the page in a new tab)
Noise left out, and words that narrow it
The topic comes with review settings chosen for these pages. Change them whenever you like once you have added it.
Leaves out changes that only mention “page last modified”, “content current as of”, “content last reviewed”.
To hear only about what matters to you, add keywords such as “semaglutide”, “tirzepatide”, “GLP-1”, “503A”, “503B”, “outsourcing facility”, “bulk drug substance”.
Comes with Team and up
Topics come with Team and up: pick the pages you want in the app and add them to a new set or one you have. On Team already? Open this topic
Team is $149 a month, for up to 400 pages.
See the Team planStart watching your first five pages. Free.
An account takes a minute: email and password, no card. Add a page, run the first check, then choose how often its set is checked.